Selected research
Market Structure
Global Oncology Biosimilars Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Oncology Biosimilars market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The US & Canada market for Oncology Biosimilars is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Oncology Biosimilars is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Oncology Biosimilars is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Oncology Biosimilars is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Oncology Biosimilars include Teva Pharmaceutical Industries Ltd, Sandoz International, Pfizer, STADA Arzneimittel AG, Intas Pharmaceuticals, Dr. Reddy’s Laboratories, Celltrion, Biocon and BIOCAD, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Includes
This report provides an overview of the global Oncology Biosimilars market and its size, analyzing global market trends based on historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Oncology Biosimilars and revenue in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Oncology Biosimilars revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering revenue and growth rates—for 2021-2032, and evaluates and forecasts the Oncology Biosimilars market size, projected growth trends, production technologies, key applications, and end-use industries.
Oncology Biosimilars Segment by Company
Teva Pharmaceutical Industries Ltd
Sandoz International
Pfizer
STADA Arzneimittel AG
Intas Pharmaceuticals
Dr. Reddy’s Laboratories
Celltrion
Biocon
BIOCAD
Apotex
Oncology Biosimilars Segment by Type
Hematopoietic Agents
Monoclonal Antibody
G-CSF
Others
Oncology Biosimilars Segment by Application
Hospital Pharmacy
Online Pharmacy
Retail Pharmacies
Oncology Biosimilars Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Oncology Biosimilars market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Oncology Biosimilars and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Oncology Biosimilars.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. Revenue of Oncology Biosimilars in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Oncology Biosimilars industry.
Chapter 3: Detailed analysis of Oncology Biosimilars companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Oncology Biosimilarsrevenue, gross margin, and recent development, etc.
Chapter 7: North America (US & Canada) by type, by application and by country, revenue for each segment.
Chapter 8: Europe by type, by application and by country, revenue for each segment.
Chapter 9: China by type, and by application, revenue for each segment.
Chapter 10: Asia (excluding China) by type, by application and by region, revenue for each segment.
Chapter 11: South America, Middle East & Africa by type, by application and by country, revenue for each segment.
Chapter 12: Concluding Insights of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Hematopoietic Agents
- Monoclonal Antibody
- G-CSF
- Others
Applications
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacies
Companies covered
- Teva Pharmaceutical Industries Ltd
- Sandoz International
- Pfizer
- STADA Arzneimittel AG
- Intas Pharmaceuticals
- Dr. Reddy’s Laboratories
- Celltrion
- Biocon
- BIOCAD
- Apotex
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Market Analysis by Type
- 1.2.1 Global Oncology Biosimilars Market Size Growth Rate by Type: 2021 VS 2025 VS 2032
- 1.2.2 Hematopoietic Agents
- 1.2.3 Monoclonal Antibody
- 1.2.4 G-CSF
- 1.2.5 Others
- 1.3 Market Analysis by Application
- 1.3.1 Global Oncology Biosimilars Market Size Growth Rate by Application: 2021 VS 2025 VS 2032
- 1.3.2 Hospital Pharmacy
- 1.3.3 Online Pharmacy
- 1.3.4 Retail Pharmacies
- 1.4 Global Market Growth Prospects
- 1.5 Global Oncology Biosimilars Growth Trends by Region
- 1.5.1 Global Oncology Biosimilars Market Size by Region: 2021 VS 2025 VS 2032
- 1.5.2 Oncology Biosimilars Market Size by Region (2021-2026)
- 1.5.3 Oncology Biosimilars Market Size by Region (2027-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
- 1.8 Years Considered
2 Global Oncology Biosimilars Market Dynamics
- 2.1 Oncology Biosimilars Industry Trends
- 2.2 Oncology Biosimilars Industry Drivers
- 2.3 Oncology Biosimilars Industry Opportunities and Challenges
- 2.4 Oncology Biosimilars Industry Restraints
3 Competitive Landscape by Company
- 3.1 Global Oncology Biosimilars Revenue by Company (2021-2026)
- 3.2 Global Oncology Biosimilars Players Revenue Ranking, 2024 VS 2025 VS 2026
- 3.3 Global Oncology Biosimilars Key Company Head office and Area Served
- 3.4 Global Oncology Biosimilars Company, Product Type & Application
- 3.5 Global Oncology Biosimilars Company Establishment Date
- 3.6 Market Competitive Analysis
- 3.6.1 Global Oncology Biosimilars Market CR5 and HHI
- 3.6.2 Global Top 5 and 10 Oncology Biosimilars Players Market Share by Revenue in 2025
- 3.6.3 2025 Oncology Biosimilars Tier 1, Tier 2, and Tier 3
4 Oncology Biosimilars Market by Type
- 4.1 Global Oncology Biosimilars Market Size by Type (2021 VS 2025 VS 2032)
- 4.2 Global Oncology Biosimilars Market Size by Type (2021-2032)
- 4.3 Global Oncology Biosimilars Market Size Share by Type (2021-2032)
5 Oncology Biosimilars Market by Application
- 5.1 Global Oncology Biosimilars Market Size by Application (2021 VS 2025 VS 2032)
- 5.2 Global Oncology Biosimilars Market Size by Application (2021-2032)
- 5.3 Global Oncology Biosimilars Market Size Share by Application (2021-2032)
6 Company Profiles
- 6.1 Teva Pharmaceutical Industries Ltd
- 6.1.1 Teva Pharmaceutical Industries Ltd Company Information
- 6.1.2 Teva Pharmaceutical Industries Ltd Business Overview
- 6.1.3 Teva Pharmaceutical Industries Ltd Oncology Biosimilars Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.1.4 Teva Pharmaceutical Industries Ltd Oncology Biosimilars Product Portfolio
- 6.1.5 Teva Pharmaceutical Industries Ltd Recent Developments
- 6.2 Sandoz International
- 6.2.1 Sandoz International Company Information
- 6.2.2 Sandoz International Business Overview
- 6.2.3 Sandoz International Oncology Biosimilars Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.2.4 Sandoz International Oncology Biosimilars Product Portfolio
- 6.2.5 Sandoz International Recent Developments
- 6.3 Pfizer
- 6.3.1 Pfizer Company Information
- 6.3.2 Pfizer Business Overview
- 6.3.3 Pfizer Oncology Biosimilars Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.3.4 Pfizer Oncology Biosimilars Product Portfolio
- 6.3.5 Pfizer Recent Developments
- 6.4 STADA Arzneimittel AG
- 6.4.1 STADA Arzneimittel AG Company Information
- 6.4.2 STADA Arzneimittel AG Business Overview
- 6.4.3 STADA Arzneimittel AG Oncology Biosimilars Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.4.4 STADA Arzneimittel AG Oncology Biosimilars Product Portfolio
- 6.4.5 STADA Arzneimittel AG Recent Developments
- 6.5 Intas Pharmaceuticals
- 6.5.1 Intas Pharmaceuticals Company Information
- 6.5.2 Intas Pharmaceuticals Business Overview
- 6.5.3 Intas Pharmaceuticals Oncology Biosimilars Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.5.4 Intas Pharmaceuticals Oncology Biosimilars Product Portfolio
- 6.5.5 Intas Pharmaceuticals Recent Developments
- 6.6 Dr. Reddy’s Laboratories
- 6.6.1 Dr. Reddy’s Laboratories Company Information
- 6.6.2 Dr. Reddy’s Laboratories Business Overview
- 6.6.3 Dr. Reddy’s Laboratories Oncology Biosimilars Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.6.4 Dr. Reddy’s Laboratories Oncology Biosimilars Product Portfolio
- 6.6.5 Dr. Reddy’s Laboratories Recent Developments
- 6.7 Celltrion
- 6.7.1 Celltrion Company Information
- 6.7.2 Celltrion Business Overview
- 6.7.3 Celltrion Oncology Biosimilars Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.7.4 Celltrion Oncology Biosimilars Product Portfolio
- 6.7.5 Celltrion Recent Developments
- 6.8 Biocon
- 6.8.1 Biocon Company Information
- 6.8.2 Biocon Business Overview
- 6.8.3 Biocon Oncology Biosimilars Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.8.4 Biocon Oncology Biosimilars Product Portfolio
- 6.8.5 Biocon Recent Developments
- 6.9 BIOCAD
- 6.9.1 BIOCAD Company Information
- 6.9.2 BIOCAD Business Overview
- 6.9.3 BIOCAD Oncology Biosimilars Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.9.4 BIOCAD Oncology Biosimilars Product Portfolio
- 6.9.5 BIOCAD Recent Developments
- 6.10 Apotex
- 6.10.1 Apotex Company Information
- 6.10.2 Apotex Business Overview
- 6.10.3 Apotex Oncology Biosimilars Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.10.4 Apotex Oncology Biosimilars Product Portfolio
- 6.10.5 Apotex Recent Developments
7 North America
- 7.1 North America Oncology Biosimilars Market Size (2021-2032)
- 7.2 North America Oncology Biosimilars Market Size by Type
- 7.2.1 North America Oncology Biosimilars Market Size by Type (2021-2026)
- 7.2.2 North America Oncology Biosimilars Market Size by Type (2027-2032)
- 7.2.3 North America Oncology Biosimilars Market Share by Type (2021-2032)
- 7.3 North America Oncology Biosimilars Market Size by Application
- 7.3.1 North America Oncology Biosimilars Market Size by Application (2021-2026)
- 7.3.2 North America Oncology Biosimilars Market Size by Application (2027-2032)
- 7.3.3 North America Oncology Biosimilars Market Share by Application (2021-2032)
- 7.4 North America Oncology Biosimilars Market Size by Country
- 7.4.1 North America Oncology Biosimilars Market Size by Country (2021 VS 2025 VS 2032)
- 7.4.2 North America Oncology Biosimilars Market Size by Country (2021-2026)
- 7.4.3 North America Oncology Biosimilars Market Size by Country (2027-2032)
- 7.4.4 North America Oncology Biosimilars Market Share by Country (2021-2032)
- 7.4.5 United States
- 7.4.6 Canada
- 7.4.7 Mexico
8 Europe
- 8.1 Europe Oncology Biosimilars Market Size (2021-2032)
- 8.2 Europe Oncology Biosimilars Market Size by Type
- 8.2.1 Europe Oncology Biosimilars Market Size by Type (2021-2026)
- 8.2.2 Europe Oncology Biosimilars Market Size by Type (2027-2032)
- 8.2.3 Europe Oncology Biosimilars Market Share by Type (2021-2032)
- 8.3 Europe Oncology Biosimilars Market Size by Application
- 8.3.1 Europe Oncology Biosimilars Market Size by Application (2021-2026)
- 8.3.2 Europe Oncology Biosimilars Market Size by Application (2027-2032)
- 8.3.3 Europe Oncology Biosimilars Market Share by Application (2021-2032)
- 8.4 Europe Oncology Biosimilars Market Size by Country
- 8.4.1 Europe Oncology Biosimilars Market Size by Country (2021 VS 2025 VS 2032)
- 8.4.2 Europe Oncology Biosimilars Market Size by Country (2021-2026)
- 8.4.3 Europe Oncology Biosimilars Market Size by Country (2027-2032)
- 8.4.4 Europe Oncology Biosimilars Market Share by Country (2021-2032)
- 8.4.5 Germany
- 8.4.6 France
- 8.4.7 U.K.
- 8.4.8 Italy
- 8.4.9 Russia
- 8.4.10 Nordic Countries
9 China
- 9.1 China Oncology Biosimilars Market Size (2021-2032)
- 9.2 China Oncology Biosimilars Market Size by Type
- 9.2.1 China Oncology Biosimilars Market Size by Type (2021-2026)
- 9.2.2 China Oncology Biosimilars Market Size by Type (2027-2032)
- 9.2.3 China Oncology Biosimilars Market Share by Type (2021-2032)
- 9.3 China Oncology Biosimilars Market Size by Application
- 9.3.1 China Oncology Biosimilars Market Size by Application (2021-2026)
- 9.3.2 China Oncology Biosimilars Market Size by Application (2027-2032)
- 9.3.3 China Oncology Biosimilars Market Share by Application (2021-2032)
10 Asia (Excluding China)
- 10.1 Asia Oncology Biosimilars Market Size (2021-2032)
- 10.2 Asia Oncology Biosimilars Market Size by Type
- 10.2.1 Asia Oncology Biosimilars Market Size by Type (2021-2026)
- 10.2.2 Asia Oncology Biosimilars Market Size by Type (2027-2032)
- 10.2.3 Asia Oncology Biosimilars Market Share by Type (2021-2032)
- 10.3 Asia Oncology Biosimilars Market Size by Application
- 10.3.1 Asia Oncology Biosimilars Market Size by Application (2021-2026)
- 10.3.2 Asia Oncology Biosimilars Market Size by Application (2027-2032)
- 10.3.3 Asia Oncology Biosimilars Market Share by Application (2021-2032)
- 10.4 Asia Oncology Biosimilars Market Size by Country
- 10.4.1 Asia Oncology Biosimilars Market Size by Country (2021 VS 2025 VS 2032)
- 10.4.2 Asia Oncology Biosimilars Market Size by Country (2021-2026)
- 10.4.3 Asia Oncology Biosimilars Market Size by Country (2027-2032)
- 10.4.4 Asia Oncology Biosimilars Market Share by Country (2021-2032)
- 10.4.5 Japan
- 10.4.6 South Korea
- 10.4.7 Taiwan
- 10.4.8 Southeast Asia
- 10.4.9 India
- 10.4.10 Australia
11 South America, Middle East & Africa
- 11.1 South America, Middle East & Africa Oncology Biosimilars Market Size (2021-2032)
- 11.2 South America, Middle East & Africa Oncology Biosimilars Market Size by Type
- 11.2.1 South America, Middle East & Africa Oncology Biosimilars Market Size by Type (2021-2026)
- 11.2.2 South America, Middle East & Africa Oncology Biosimilars Market Size by Type (2027-2032)
- 11.2.3 South America, Middle East & Africa Oncology Biosimilars Market Share by Type (2021-2032)
- 11.3 South America, Middle East & Africa Oncology Biosimilars Market Size by Application
- 11.3.1 South America, Middle East & Africa Oncology Biosimilars Market Size by Application (2021-2026)
- 11.3.2 South America, Middle East & Africa Oncology Biosimilars Market Size by Application (2027-2032)
- 11.3.3 South America, Middle East & Africa Oncology Biosimilars Market Share by Application (2021-2032)
- 11.4 South America, Middle East & Africa Oncology Biosimilars Market Size by Country
- 11.4.1 South America, Middle East & Africa Oncology Biosimilars Market Size by Country (2021 VS 2025 VS 2032)
- 11.4.2 South America, Middle East & Africa Oncology Biosimilars Market Size by Country (2021-2026)
- 11.4.3 South America, Middle East & Africa Oncology Biosimilars Market Size by Country (2027-2032)
- 11.4.4 South America, Middle East & Africa Oncology Biosimilars Market Share by Country (2021-2032)
- 11.4.5 Brazil
- 11.4.6 South Africa
- 11.4.7 Saudi Arabia
- 11.4.8 Turkey
- 11.4.9 Argentina
- 11.4.9 UAE
- 11.4.9 Egypt
- 11.4.9 Chile
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
- 13.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst